Osteoprotegerin: A Novel Independent Marker for Silent Myocardial Ischemia in Asymptomatic Diabetic Patients

• DOI: 10.2337/dc07-0992
• Publication Date: 2007-10-26T16:15:43Z
• Authors: Antoine Avignon; Ariane Sultan; Christophe Piot; Denis Mariano-Gou...; Jean-François Th...; Jean Paul Cristol; Anne Marie Dupuy
• Keywords: Univariate analysis

We sought to evaluate osteoprotegerin, an inhibitor of osteoclastogenesis involved in atherosclerosis, and other novel risk factors as predictive markers silent myocardial ischemia (SMI).A total 465 consecutive diabetic patients with more than one additional factor were evaluated for SMI using stress perfusion imaging (MPI). studied the association (positive electrocardiogram and/or abnormal MPI) (lipoprotein[a], homocysteine, adiponectin, C-reactive protein, fibrinogen), conventional (total, LDL, HDL cholesterol triglycerides).A 92 diagnosed SMI. Of six markers, osteoprotegerin was only associated SMI; relative (RR) values above 75th percentile 3.19 (95% CI 1.99-5.18; P < 0.001) comparison those below percentile. In univariate analyses, plasma significantly higher triglycerides (P = 0.04) lower 0.02). The remained significant after correcting variables at 0.15 analysis (RR 3.95 [95% 2.21-7.06]; 0.0001). observed male 0.0001) female 0.03) patients, type 1 0.002) 2 0.0004) or without nephropathy, but not 0.2) peripheral arterial disease.Osteoprotegerin measurement, together factors, can help better define population increased likelihood